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Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic
syndrome of hypophosphatemia, decreased renal phosphate reab-
sorption, normal or low serum 1,25-dihydryxyvitamin-D concen-
tration, myopathy, and osteomalacia. Fibroblast growth factor 23
(FGF23) is a phosphaturic protein overexpressed in tumors that
cause TIO and is, at least partly, responsible for the manifestations
of TIO.
Objective: The objective of this study was to determine the sensi-
tivity of FGF23 measurements in TIO.
Design: FGF23 concentrations were measured on stored samples
with three ELISAs.
Setting: This study was conducted at subspecialty referral centers.
Patients: Twenty-two patients with suspected TIO, 13 with con-
firmed tumors, were studied.
Interventions: There were no interventions in this study.
Main Outcome Measure: FGF23 concentration was the main out-
come measure of this study.
Results: Elevated FGF23 concentrations were detected using the
Immunotopics C-terminal assay in 16 of 22 TIO patients (for a sen-
sitivity of 73%), the Immunotopics Intact assay in five of 22 patients
(sensitivity, 23%), and the Kainos Intact assay in 19 of 22 patients
(sensitivity, 86%). In the 13 patients with confirmed tumors, the
sensitivity was higher with all assays: 92% for the Immunotopics
C-terminal assay, 38% for the Immunotopics Intact assay, and 100%
for the Kainos assay.
Conclusion: The Kainos Intact assay was the most sensitive, fol-
lowed by the Immunotopics C-terminal assay. The findings of normal
FGF23 concentrations in some patients with TIO may indicate that
FGF 23 is not responsible for the hypophosphatemia in these patients
or that FGF23 secretion by some tumors is partially responsive to serum
phosphate. Normal FGF23 concentrations should be interpreted in re-
lation to the serum phosphate and 1,25-dihydryxyvitamin-D concentra-
tions. (J Clin Endocrinol Metab 91: 2055–2061, 2006)
TUMOR-INDUCED OSTEOMALACIA (TIO) is a para-neoplastic syndrome consisting of hypophosphatemia,
decreased renal tubular phosphate reabsorption, inappro-
priately normal or low serum 1,25-dihydroxyvitamin D con-
centrations, myopathy, and osteomalacia. Patients typically
present with a history of chronic bone pain, fractures, and
proximal muscle weakness. Children may present with poor
growth and lower extremity deformity resulting from rick-
ets. The tumors are often benign, small, and difficult to locate
with conventional imaging techniques. Fibroblast growth
factor 23 (FGF23) is a secreted peptide hormone overpro-
duced by the tumor in patientswith TIO (1–4), which inhibits
renal phosphate reabsorption resulting in hypophos-
phatemia (4, 5). Surgical excision results in resolution of
hypophosphatemia, osteomalacia, muscle weakness (1, 3,
6–8), and the normalization of plasma FGF23 (1, 3, 6, 7, 9, 10).
FGF23 was identified by positional cloning as the gene
responsible for autosomal dominant hypophosphatemic
rickets (11). Mutations involve a RXXR amino acid sequence
cleavage site and make the protein resistant to cleavage by
proteases (5, 11–13). Subsequently, circulating FGF23 was
found to be elevated in patients with X-linked hypophos-
phatemic rickets (XLH), TIO, and fibrous dysplasia in plasma
and serum in separate studies (1, 3, 4, 6, 7, 14). These disorders
all involve renal phosphatewasting andosteomalacia as central
abnormalities. In addition, plasma or serum FGF23 is elevated
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in patients with renal failure and correlates positively with
serum creatinine and phosphate concentrations (15, 16).
Because FGF23 is a major etiological factor in several dis-
eases of phosphate homeostasis, it is important to develop
informative assays for plasma or serum FGF23 that will be
clinically and diagnostically useful. Previous studies report-
ing either plasma or serum FGF23 in TIO have typically used
one assay and have not assessed the sensitivity of FGF23
assays. The goal of the current study was to measure FGF23
concentrations using three different assays, comparing their
sensitivity in 22 patients with clinical TIO (13 of which had
confirmed tumors).
Patients and Methods
Patients
Patients with evidence of an acquired phosphate wasting disorder
were recruited from the metabolic bone clinic at Indiana University
Hospital (Indianapolis, IN) and from the clinical practices of collabo-
rators. Control subjects were 118 healthy subjects with normal serum
calcium, phosphate, and renal function from our study database. The
study was approved by the Indiana University-Purdue University In-
dianapolis and Clarian Institutional Review Board, and written in-
formed consent was obtained from all patients.
Twenty-two patients with confirmed or presumptive diagnosis of
TIO underwentmeasurement of plasma FGF23 concentrations (Table 1).
Patient ages ranged from 11–79 yr. Patients 2, 3, 14, and 17 were pre-
viously included in a paper by Jonsson et al. (3) describing levels of
plasma FGF23 measured by the C-terminal Immunotopics assay. Pa-
tients 5, 10, 12, and 21 were previously described in case reports (6, 7,
9, 17). Clinical diagnosis of TIO was made by presence of hypophos-
phatemia, renal phosphate wasting, low or inappropriately normal se-
rum 1, 25-dihydroxyvitamin D, proximal muscle weakness, and bone
pain. Patients were excluded if they had a family history of hypophos-
phatemia, XLH, or autosomal dominant hypophosphatemic rickets.
Thirteen patients had a confirmed tumor. In 10 patients, tumor removal
resulted in improvement of symptoms. In one patient, the tumorwas not
completely resectable (patient 21), and another patient had an unre-
sectable brain tumor (patient 16), whereas patient 17 refused surgery for
a maxillary sinus hemangiopericytoma. Patient 7 had a leg tumor re-
moved without change in his hypophosphatemia.
Blood and urine samples were obtained in the morning after an
overnight fast. Blood was collected in EDTA tubes and serum separator
tubes, centrifuged, and separated into plasma or serum. Samples were
frozen at 80 C until testing. The tubular maximum reabsorption of
phosphate per deciliter of glomerular filtrate (TMP/GFR)was estimated
using the nomogram method described by Walton and Bijvoet (18) (see
Table 1). Most patients were being treated with oral phosphate supple-
ments and calcitriol. Serum and urine chemistries were measured in the
respective clinical laboratories used by the clinicians involved in the
individual patient’s care.
Assays
FGF23 concentrations were measured in each patient using three
different two-site enzyme-linked immunosorbent assays: a C-terminal
human FGF23 ELISA (Immunotopics, San Clemente, CA), an intact
human FGF23 ELISA (Immunotopics), and another intact human FGF23
ELISA (Kainos Laboratories, Tokyo, Japan) (1). The C-terminal assay
uses polyclonal antiserum and recognizes two epitopes on the C-ter-
minal side of theRXXR cleavage site and thus recognizes both full-length
FGF23 and C-terminal cleavage fragments of FGF23. The Immunotopics
Intact assay uses polyclonal antiserum to epitopes on both sides of the
cleavage site, whereas the Kainos Intact assay uses two monoclonal
antibodies to epitopes on either side of the cleavage site. For the two
TABLE 1. Preoperative values in patients with TIO
Patient Sex Age (yr) Tumor Cure Phosphorous(mg/dl)
Creatinine
(mg/dl)
TMP/GFR
(mg/dl)
Immunotopics
C-terminal (RU/ml)
(72.9  38.2)b
Immunotopics
Intact (pg/ml)
(13.3  19.0)b
Kainos Intact
(pg/ml)
(29.7  20.7)b
1 M 52 Removeda Y 2.3 1.7 1.9 706.8 1 554.9
2 F 62 2.0 1.1 1.7 281.7 35.3 213.4
3 M 61 1.9 0.9 2.0 1,346.5 22.3 921.2
4 M 79 1.7 1.0 1.1 24.7 1 15.5
5 F 14 Removeda Y 1.9 0.6 0.7 287.0 1 359.5
6 M 37 Removeda Y 2.1 1.4 135.3 3.3 87.6
7 M 12 Removed N 2.0 0.5 1.6 158.8 13.5 111.5
8 M 34 1.2 0.9 0.7 96.6 9.4 239.1
9 F 55 1.5 0.6 1.3 95.6 10.3 39.4
10 M 11 Removeda Y 1.5 0.5 1.1 3,143.0 87.8 402.2
11 M 60 1.8 1.0 0.7 42.4 1 107.1
12 M 42 Removeda Y 1.7 1.1 1.2 483.6 50.5 397.6
13 F 36 Removeda Y 1.2 0.9 1.3 954.0 6.9 1,919.8
14 F 44 Removeda Y 1.4 0.6 1,274.1 47.2 816.2
15 F 68 Removeda Y 0.7 1.0 0.7 277.3 61.4 1,230.8
16 M 22 Unresectablea 2.2 0.9 0.9 357.4 62.3 442.7
17 F 33 Biopsy positivea 1.3 0.8 0.2 1,625.2 60.2 500.6
18 F 45 2.3 0.7 1.7 75.1 10.8 58.9
19 M 50 Removeda Y 1.8 1.1 1.2 250.7 1 146.0
20 F 43 2.0 0.7 255.1 41.7 363.6
21 M 52 Partial resectiona N 1.2 0.9 0.3 2,050.8 48.2 4,450.0
22 F 61 Removeda Y 0.8 0.5 10,642.5 426.6 9,320.0
FGF23 values greater than normal 16 5 19
Sensitivity in clinical TIO 0.73 0.23 0.86
Sensitivity, confirmed tumor 0.92 0.38 1.00
Phosphorus and creatinine values are in mg/dl. The Immunotopics C-terminal results are in relative units per ml (RU/ml), whereas the
Immunotopics Intact andKainos Intact assay results are in pg/ml. For SI conversions of creatinine to mol/liter, multiply by 88.4, and to convert
phosphate to mmol/liter, multiply by 0.32.
a Subjects with confirmed tumor (n  13) (patients 1, 5, 6, 10, 12, 13, 14, 15, 16, 17, 19, 21, and 22).
b For each assay, the mean  SD is in parentheses.
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intact assays, the capture antibody recognizes an epitope on one side of
the RXXR cleavage site, whereas the detection antibody recognizes an
epitope on the other side; thus, the assays only recognize the intact
molecule. The FGF23 assays were performed using stored plasma or
serum according to the specified kit directions. Inter- and intraassay
coefficients of variation for the three assays as reported by the manu-
facturers are as follows. The Immunotopics C-terminal FGF23 assay has
an intraassay coefficient of variation of 5.0%, an interassay coefficient of
variation of 5.0–7.3%, and a lower limit of detection of 3.0 relative units
(RU)/ml. The Immunotopics Intact FGF23 assay has an intraassay co-
efficient of variation of 2.6–4.4%, an interassay coefficient of variation
of 6.1–6.5%, and a lower limit of detection of 1.0 pg/ml. The Kainos
Intact FGF23 assay has a lower limit of detection of 3 pg/ml and in-
traassay and interassay coefficients of variation of less than 5%. The
C-terminal assay measures FGF23 in RU per milliliter, based on the
initial standardization procedures used by the manufacturers (3),
whereas both intact assays are standardized to measure FGF23 in pi-
cograms per milliliter.
Analysis
Data were analyzed and graphed using Microsoft Excel (Microsoft
Corporation, Redmond, WA). Pearson’s correlation was calculated be-
tween the FGF23 concentrations from each assay and the corresponding
serum phosphate. FGF23 values in TIO subjects using different assays
were compared on logarithmic graphs to normalize the distribution and
compared using Pearson’s correlation. The paired Student’s t test for
means was used for comparison between presurgical and postsurgical
values.
Results
Reference ranges were determined by testing samples
from 118 normophosphatemic individuals with all three as-
says. This included eight samples from children 2–14 yr. The
110 adult samples were from subjects 20–83 yr. The control
mean  sd for each assay was as follows: for the Immuno-
topics C-terminal assay, 72.9  38.2 RU/ml; for the Immu-
notopics Intact assay, 13.3  19.0 pg/ml; and for the Kainos
Intact assay, 29.7  20.7 pg/ml. The normal range for each
assaywas defined as themeanplus two sds in controls. There
was no difference between healthy children and adults for
theC-terminal assay using the same 110 healthy adults 20–83
yr (71.8  38.1 RU/ml) and 60 healthy children 1–17 yr
(71.1  35.7 RU/ml). The phosphate range in children was
3.6–5.4 mg/dl, appropriate for age, whereas the phosphate
range in adults was 2.4–4.4 mg/dl.
The results of the three FGF23 assays in patients with TIO
are shown in Table 1. Figure 1 compares the values in TIO
patients with the normal ranges. Sensitivity was defined as
the ability to detect FGF23 concentrations above the normal
range for each assay in subjects with TIO. For the Immuno-
topics C-terminal assay, 16 of 22 patients had values above
the normal range, providing a sensitivity of 73% for TIO.
With the Immunotopics Intact assay, five patients had values
above the normal range, resulting in 23% sensitivity. With
the Kainos assay, 19 patients had values above the normal
range, giving a sensitivity of 86%. However, when only pa-
tients with confirmed tumors (n  13) were included in this
analysis, the sensitivity was 92% for the Immunotopics C-
terminal assay, 38% for the Immunotopics Intact assay, and
100% for the Kainos assay.
Although most TIO patients had elevated FGF23 concen-
trations, some patients had FGF23 concentrations in the nor-
mal range. Most patients had concentrations greater than the
mean for normal controls. Twenty patients had FGF23 levels
higher than themean on the Immunotopics C-terminal assay,
12 had FGF23 levels greater than the mean with the Immu-
notopics Intact assay, and 21were greater than themeanwith
the Kainos assay. Five patients had undetectable FGF23 con-
centrations by the Immunotopics Intact assay. Patients 4, 9,
and 18 had FGF23 concentrations in the normal range with
all three assays. However, patient 9 had subsequent repeat
measurement of FGF23, which was elevated on the Kainos
assay (126.0 pg/ml) but not the Immunotopics C-terminal
assay (137.6 RU/ml) (the Immunotopics Intact assay was not
repeated). Patient 18 had hypophosphatemia and osteoma-
lacia on bone biopsy with normal FGF23 levels on all three
assays. Of interest, none of these patients had confirmation
of a tumor, but their clinical features were consistent with
TIO rather than an inherited disorder or Fanconi’s syndrome.
Patients 6 and 11 had elevated FGF23 only on the Kainos
assay, although patient 6 (in whom a tumor was confirmed)
had a C-terminal FGF23 concentration near the upper limit
of normal. Patients 1 and 6 also had mild renal insufficiency.
Relationships between FGF23 assays were examined
graphically (Fig. 2, A–C), and Pearson’s correlations were
calculated. The highest correlation occurred between the Im-
munotopics C-terminal and the Kainos Intact assayswith r
0.86 (P 0.01). Comparison of the Immunotopics C-terminal
with the Immunotopics Intact assays resulted in r 0.65 (P
0.01), and comparison of the Kainos Intact assay with the
Immunotopics Intact assay resulted in r  0.59 (P  0.01).
In light of the higher sensitivity of the Immunotopics C-
terminal and Kainos Intact assays, we measured preopera-
tive and postoperative samples with these two assays in nine
FIG. 1. FGF23 concentrations as measured by three different assays
for 22 patients with TIO. The shaded columns indicate the range in
healthy controls for each assay, defined as mean  2 SD. The mean
normal value for each assay is indicated by a horizontal bar in the
column.
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patientswhounderwent surgery for TIO (Fig. 3,A andB). For
this analysis, the closest preoperative sample to the surgery
was used. For patients 12, 15, and 21, this was a later sample
than the one used in Table 1 and reflected changes in the
FGF23 concentration with time. Most postoperative samples
were between 1 and 2 d after surgery. All patients had a
decrease in their FGF23 concentrations on both the Immu-
notopics C-terminal assay and the Kainos Intact assays. By
C-terminal assay, the mean preoperative concentration was
1119.2  941.6 RU/ml, and the mean postoperative concen-
trationwas 256.0 276.1 RU/ml (P 0.028). ByKainos Intact
assay, the mean preoperative concentration was 934.0 
1114.5 pg/ml, and themeanpostoperative concentrationwas
61.0  88.1 pg/ml (P  0.037).
Four patients in Fig. 3 continued to have elevated C-
terminal results after surgery, whereas two had elevated
Kainos Intact assay results. Patient 1 had renal insufficiency
and persistent elevations of C-terminal FGF23 after surgery,
despite normalization ofKainos Intact FGF23 andphosphate.
Patient 14 had a first postoperative sample at 6 months that
was elevated on the C-terminal assay but not on the Kainos
Intact assay. She was treated with radiation therapy because
of pathological features of malignant osteosarcoma. Her sub-
sequent C-terminal FGF23 was normal (82.3 RU/ml), with
FIG. 2. A–C, Relationship between FGF23 assay results in patients
with TIO. The upper limit of normal for each assay is indicated on the
graph, defined as mean  2 SD for normophosphatemic control sub-
jects. P  0.01 for each comparison.
FIG. 3. A and B, Preoperative and postoperative FGF23 concentra-
tions as measured by the Immunotopics C-terminal (A) and the Kai-
nos Intact (B) assays in nine patients who had surgery for TIO. The
shaded regions represent the normal ranges for each assay. Patients
1, 5, 10, 12, 13, 14, 15, 19, and 21 are included in this figure. Of these
subjects, only patient 21 was not cured by his surgery, and his FGF23
concentrations remained quite elevated. Most postoperative samples
are from 1–2 d postoperatively. One patient had the postoperative
sample drawn at 2 h. Two other patients had their earliest postop-
erative samples drawn at 6 and 8 months after surgery.
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normal Kainos assay, and her hypophosphatemia resolved.
The only postoperative sample for patient 15 was 2 h post-
surgery, which was elevated on both assays. However, she
rapidly normalized her phosphate and weaned off all med-
ications. Patient 21 had a partial resection of a tumor, and his
FGF23 levels declined but remained elevated on both assays.
His phosphate improved but did not normalize.
Despite variability in FGF23 concentrations among pa-
tients with similar phosphate concentrations, there was an
inverse correlation between phosphate and FGF23 concen-
trations measured by all three assays. r values with phos-
phate for the Immunotopics C-terminal, Immunotopics In-
tact, and Kainos assays were 0.50, 0.50, and 0.57
respectively (P  0.05).
Discussion
TIO is an acquired disorder characterized by phosphate
wasting and impaired vitamin D metabolism. Tumors that
cause TIO markedly overexpress FGF23 (2–4, 19, 20). The
current study is the largest series of TIO patients with mea-
sured circulating FGF23 concentrations and, to our knowl-
edge, the only series to compare the performance of three
different FGF23 assays in a phosphate wasting disorder.
Although a wide variety of tumors have been reported to be
responsible for this paraneoplastic syndrome, recent evi-
dence indicates that the majority (84%) are phosphaturic
mesenchymal tumors/mixed connective tissue variant (20).
FGF23 concentrations have also been reported to be elevated
in other phosphate wasting disorders including XLH (3) and
fibrous dysplasia (14). Thus, FGF23 assays may be clinically
useful in a variety of patients with disorders of phosphate
homeostasis.
In the current study, we compared the sensitivity of three
different assays in a large group of patients with TIO. Our
data demonstrate that two of the three assays had high sen-
sitivity for TIO, and results were highly correlated. The sen-
sitivity of the Immunotopics Intact assay was poor. There
were 14 cases in which the FGF23 concentration in TIO was
low or normal using this assay, with elevated FGF23 con-
centrations using one or both of the other assays. This in-
cluded eight patientswith confirmed tumors. The differences
between assays may be due to differential production of
full-length or cleavage products of FGF23 in tumors. The
average ratio of C-terminal assay to Kainos assay values was
1.51. However, there was considerable variation in this ratio
(range, 0.23–3.25), suggesting that the proportion of full-
length and cleaved FGF23 is not constant among cases of TIO.
The diagnosis of TIO is difficult and frequently made
clinically in patients for whom no other cause of renal phos-
phate wasting is found. Indeed, many patients have their
disorder for years before localization and removal of the
causative tumor (including some patients for whom surgery
was curative in this series). There is a general bias to only
report those cases in which tumor removal completely cures
the disorder. To address the larger clinical context, we have
also included patients for whom tumors have not yet been
found. Thus, we are able to compare FGF23 concentrations
in subjects with a clinical diagnosis of TIO as well as in those
with a confirmed tumor.Most subjects inwhom tumorswere
found were cured by removal of the tumor. Our data also
demonstrate that patients inwhom tumors are localizable are
more likely to have elevated FGF23 concentrations. This may
be due to greater FGF23 production in larger tumors. How-
ever, many subjects without localized tumor also have quite
elevated levels.
Tumors that are detected still might not be responsible for
TIO, especially if the syndrome is not cured or improved by
surgery. Likewise, tumors causing TIO may remain unde-
tected. Our series includes some subjectswhowere not cured
by tumor removal. Patient 7 had a benign leg tumor removed
and remained hypophosphatemic. Patient 21 refused ampu-
tation for an extensive foot tumor, but debulking resulted in
a partial response in FGF23 and phosphate concentrations.
Patient 16 had a brain tumor that was not amenable to sur-
gery. A magnetic resonance image of patient 17 revealed an
extensive maxillary sinus tumor, and biopsy demonstrated
features of hemangiopericytoma, a tumor type associated
with TIO. However, if only those 10 patients for whom sur-
gery resulted in clinical cure are analyzed, the sensitivity of
the C-terminal assay was 90% and of the Kainos assay was
100%. Smaller tumors may secrete less FGF23 while being
more difficult to locate. Because the diagnosis of TIO is oth-
erwise clinical, evaluating FGF23 concentrations both in sub-
jects with and without confirmed tumor is valuable and
confirms the role of FGF23 in this phosphate wasting
disorder.
Interestingly, patients 1 and 6 had both tumors and renal
insufficiency. Patient 6 had mild renal insufficiency with a
creatinine of 1.4, elevated full-length FGF23 with the Kainos
assay, and high normal results with the C-terminal assay.
FGF23 concentrations may have been increased by the pres-
ence of renal insufficiency, but his hypophosphatemia re-
solved after removal of a tumor in his foot. Postoperative
FGF23 valueswere not available. The FGF23 concentration of
patient 1 was elevated on the Immunotopic C-terminal and
Kainos Intact assays (but undetectable on the Immunotopics
Intact assay), and phosphate wasting necessitated treatment
with calcitriol and oral phosphate. Six weeks after tumor
removal, his serum phosphate, TMP/GFR, and renal func-
tion improved. Serum phosphate increased from 2.3 to 3.6
mg/dl, creatinine decreased from 1.7 to 1.3 mg/dl, and
TmP/GFR increased from1.9 to 2.9mg/dl. After surgery, the
intact FGF23 concentration decreased with the Kainos assay
but remained elevated when measured by the C-terminal
assay. This may suggest persistence of C-terminal fragments
of FGF23 due to mild renal impairment in our patient, con-
sistent with the observation of increased circulating FGF23 in
patients with renal insufficiency as described by others using
the C-terminal FGF23 assay (15, 16). However, elevations of
full-length FGF23 (Kainos assay) in the setting of renal failure
have also been reported (21–23). Renal failuremay contribute
to the elevations of FGF23 seen in patients 1 and 6. However,
in patient 1, only the intact FGF23 measured by the Kainos
assay decreased after surgery. The decrease in the FGF23
concentrationwith theKainos assay suggests that this patient
had more C-terminal fragments than intact FGF23 postop-
eratively. The ratio of C-terminal FGF23/Kainos Intact
FGF23 was 1.3 preoperatively and 8.2 postoperatively in
patient 1. This differs from results reported by Imanishi et al.
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(Imanishi, Y., personal communication; Ref. 16), who noted
no difference in the ratio of circulating intact/C-terminal
FGF23 in patients with renal failure compared with control
subjects using the Immunotopics Intact and C-terminal as-
says. This may represent differences between the Immuno-
topics Intact and Kainos assays, or there may be differences
in the rate of decline of full-length or cleavage fragments of
FG23 after tumor removal in the setting of abnormal and
changing renal function.
In our study, the majority of TIO patients had a measur-
ably elevated serumFGF23 concentration, and the sensitivity
for two of the assays (Immunotopics C-terminal assay 73%
and Kainos assay 86%) for clinical TIO corresponds well to
the immunohistochemistry findings of Folpe et al. (20), who
found 81% of TIO tumors expressed FGF23. One of the chal-
lenges in evaluating TIO is that some patients have clinical
and biochemical presentations consistent with TIO, despite
a negative search for a tumor using various imaging mo-
dalities. When only the patients with surgically confirmed
tumors were analyzed, the sensitivity increased to 92% for
the Immunotopics C-terminal assay and 100% for the Kainos
assay but was only 38% for the Immunotopics Intact assay.
The fact that some patients did not have elevations of
FGF23 (with one or more assay) may indicate that there are
limitations in currently available assays. Alternatively, in
some cases, the clinical picture may not be caused by in-
creased circulating FGF23, and some tumors may express
other substances responsible for osteomalacia andphosphate
wasting. In this regard, Jan De Beur et al. (19) demonstrated
that TIO tumors overexpress matrix extracellular phospho-
glycoprotein, frizzled-related protein-4 (FRP-4), and other
genes. Berndt et al. (24) subsequently demonstrated phos-
phaturic actions to FRP-4 infusions in normal rats. However,
the single TIO patient described by Berndt et al. did not have
an elevated serum FRP-4. In addition, Carpenter et al. (25)
reported the expression of FGF7 in a tumor responsible for
TIO. Although most tumors causing TIO produce FGF23,
elevated circulating FGF23 concentrations may not be re-
quired to define TIO. Finally, as observed in other endocrine
tumors, it is possible that some tumors may continue to be
partially responsive to the metabolic state of the patient.
Therefore, it may be necessary to interpret FGF23 levels in
light of serum phosphate and calcitriol concentrations. In the
setting of hypophosphatemia and low calcitriol concentra-
tions, FGF23 levels in the mid- to upper normal range may
be inappropriate. Despite hypophosphatemia in all of our
TIO patients, only one patient had serum FGF23 levels less
than the normal mean with the Kainos assay, and two were
less than the normal mean with the C-terminal assay. An
appropriate response to hypophosphatemia would be to de-
crease the production of a phosphaturic hormone (FGF23) to
allow for improved renal tubular reabsorption to normalize
the phosphate.
Recently, studies have indicated regulation of FGF23 gene
expression by 1,25-dihydroxyvitaminD, aswell as regulation
of 1,25-dihydroxyvitamin D production by FGF23 (26–29).
This would emphasize the importance of the common
finding that disorders associated with FGF23 excess have
inappropriately low or normal 1,25-dihydroxyvitamin D
concentrations. Conversely, for appropriate physiological
regulation, FGF23 concentrations should be low in the setting
of low 1,25-dihydroxyvitamin D and hypophosphatemia. To
accurately correlate the FGF23 concentrations with the phos-
phate concentrations or 1,25-dihydroxyvitamin D concen-
trations, these need to be measured simultaneously. Our
subjects were on treatment with calcitriol and phosphate at
the time of the sampling for FGF23. Consequently, 1,25-
dihydroxyvitamin D measurements were not performed on
these samples. Future studies should attempt to correlate
FGF23with 1,25 dihydroxyvitaminD concentrations in phos-
phate wasting disorders and determine the effect, if any, of
treatment with calcitriol on FGF23 in these disorders.
In summary, for the Immunotopics C-terminal and Kainos
Intact FGF23 assays, FGF23 concentrations were elevated in
most patients with a clinical and biochemical presentation
consistent with TIO, especially in patients with identifiable
tumors. Reliable FGF23 assays have the potential to be clin-
ically useful in the diagnosis and management of disorders
of phosphate homeostasis. Additionally, FGF23 concentra-
tions may help determine the cause of hypophosphatemia
and may also one day be useful in localizing tumors (30).
FGF23 concentrations may need to be interpreted in the
context of the serum phosphate and possibly 1, 25-dihy-
droxyvitamin D concentrations.
Acknowledgments
We thank Dr. Kenneth White for valuable scientific input and
comments.
Received September 21, 2005. Accepted March 10, 2006.
Address all correspondence and requests for reprints to: Michael
Econs, M.D., Indiana University School of Medicine, 541 North Clinical
Drive, Clinical Building 459, Indianapolis, Indianapolis 46202. E-mail:
mecons@iupui.edu.
This work was supported by National Institutes of Health Grants
R01AR42228, T32 AR 07581-09, and MO1 RR00750.
References
1. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeu-
chi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased cir-
culatory level of biologically active full-length FGF-23 in patients with hy-
pophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960
2. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M,
Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T,
Strom TM, Juppner H, Econs MJ 2001 The autosomal dominant hypophos-
phatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by
tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497–500
3. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y,
Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM,
Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor
23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med
348:1656–1663
4. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y,
Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of
FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci
USA 98:6500–6505
5. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi
Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for
autosomal dominant hypophosphatemic rickets is resistant to proteolytic
cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179–3182
6. Ward L, Rauch F, White K, Filler G, Matzinger M, Letts M, Travers R, Econs
M, Glorieux F 2004 Resolution of severe, adolescent-onset hypophosphatemic
rickets following resection of an FGF-23-producing tumour of the distal ulna.
Bone 34:905–911
7. Hoogendoorn EH, White KE, Econs MJ, Hermus AR 2003 Hypophos-
phatemia, osteomalacia and proximal muscle weakness treated by surgery.
Clin Endocrinol (Oxf) 58:796–797
8. Nelson AE, Robinson BG, Mason RS 1997 Oncogenic osteomalacia: is there
a new phosphate regulating hormone? Clin Endocrinol (Oxf) 47:635–642
2060 J Clin Endocrinol Metab, June 2006, 91(6):2055–2061 Imel et al. • FGF23 Measurements in TIO
9. Shulman DI, Hahn G, Benator R, Washington K, White KE, Farber J, Econs
MJ 2004 Tumor-induced rickets: usefulness ofMRgradient echo recall imaging
for tumor localization. J Pediatr 144:381–385
10. Nelson AE, Bligh RC,MiramsM, Gill A, Au A, Clarkson A, Juppner H, Ruff
S, Stalley P, ScolyerRA,RobinsonBG,MasonRS, Bligh PC 2003Clinical case
seminar: fibroblast growth factor 23: a new clinical marker for oncogenic
osteomalacia. J Clin Endocrinol Metab 88:4088–4094
11. ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is
associated with mutations in FGF23. Nat Genet 26:345–348
12. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom
TM 2004 FGF23 is processed by proprotein convertases but not by PHEX. Bone
35:455–462
13. WhiteKE, CarnG, Lorenz-Depiereux B, Benet-PagesA, StromTM, EconsMJ
2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations sta-
bilize FGF-23. Kidney Int 60:2079–2086
14. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE,
Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Gehron Robey P
2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phos-
phate wasting. J Clin Invest 112:683–692
15. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating
concentration of FGF-23 increases as renal function declines in patients with
chronic kidney disease, but does not change in response to variation in phos-
phate intake in healthy volunteers. Kidney Int 64:2272–2279
16. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A,
MiuraM,Miyauchi A, Kobayashi K,Miki T, Shoji T, Ishimura E, Nishizawa
Y 2004 FGF-23 in patients with end-stage renal disease on hemodialysis.
Kidney Int 65:943–946
17. Zimering MB, Caldarella FA, White KE, Econs MJ 2005 Persistent tumor
induced osteomalacia confirmed by elevated post-operative levels of serum
FGF-23. Endocr Pract 11:108–114
18. Walton RJ, Bijvoet OLM 1975 Nomogram for derivation of renal threshold
phosphate concentration. Lancet 2:309–310
19. Jan De Beur SM, Finnegan RB, Vassiliadis J, Cook B, Barberio D, Estes S,
Manavalan P, Petroziello J, Madden SL, Cho JY, Kumar R, Levine MA,
Schiavi SC 2002 Tumors associated with oncogenic osteomalacia express
genes important in bone and mineral metabolism. J Bone Miner Res 17:1102–
1110
20. Folpe A, Fanburg-Smith J, Billings S, Bisceglia M, Bertoni F, Cho J, Econs
M, Inwards C, Jan de Beur S, Mentzel T, Montgomery E, Michal M, Miet-
tinenM,Mills S, Reith J, O’Connell J, Rosenberg A, Rubin B, Sweet D, Vinh
T, Wold L, Wehrli B, White K, Zaino R, Weiss S 2004 Most osteomalacia-
associatedmesenchymal tumors are a single histopathologic entity: an analysis
of 32 cases and a comprehensive review of the literature. Am J Surg Pathol
28:1–30
21. Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo F,
FukagawaM 2004 Possible involvement of circulating fibroblast growth factor
23 in the development of secondary hyperparathyroidism associated with
renal insufficiency. Am J Kidney Dis 44:250–256
22. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S,
Gejyo F, Shigematsu T, Fukagawa M 2005 Serum fibroblast growth factor-23
levels predict the future refractory hyperparathyroidism in dialysis patients.
Kidney Int 67:1171–1178
23. Kazema JJ, Sato F, Omori K, Yamamoto S, Maruyama H, Narita I, Gejyo F,
Fukagawa M 2005 Pretreatment serum FGF-23 levels predict the efficacy of
calcitriol therapy in dialysis patients with secondary hyperparathyroidism.
Kidney Int 67:1120–1125
24. Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De
Beur SM, Schiavi SC, Kumar R 2003 Secreted frizzled-related protein 4 is a
potent tumor-derived phosphaturic agent. J Clin Invest 112:785–794
25. Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R
2005 FGF7, an inhibitor of phosphate transport derived from oncogenic os-
teomalacia-causing tumors. J Clin Endocrinol Metab 90:1012–1020
26. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE 2005 Genetic dissection of
phosphate- and vitamin D-mediated regulation of circulating Fgf23 concen-
trations. Bone 36:971–977
27. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita
T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator
of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:
429–435
28. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R,
Kuwahata M, Miyamoto K 2005 Vitamin D and phosphate regulate fibroblast
growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288:E1101–
E1109
29. Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa
H, Miyamoto K, Fukushima N 2005 Circulating FGF-23 is regulated by 1al-
pha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–
2549
30. Takeuchi Y, SuzukiH,Ogura S, ImaiR, Yamazaki Y, Yamashita T,Miyamoto
Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T 2004 Venous
sampling for fibroblast growth factor-23 confirms preoperative diagnosis of
tumor-induced osteomalacia. J Clin Endocrinol Metab 89:3979–3982
JCEM is published monthly by The Endocrine Society (http://www.endo-society.org), the foremost professional society serving the
endocrine community.
Imel et al. • FGF23 Measurements in TIO J Clin Endocrinol Metab, June 2006, 91(6):2055–2061 2061
